Summary
53 / 100 · Bulios Score
What speaks for it
- Revenue grew by 215% a year over the last 3 years.
- It holds more cash than debt: $47.5M against $2.46M.
- Out of every 100 USD of revenue, 18 USD is left as free cash.
What to watch
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 0.6 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 937.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 120% a year over 5 years. Over the last 3 years it grew by 215% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 13 USD
- Research and development 39 USD
- Sales and administration 50 USD
- Taxes and other -2.5 USD
- Net profit 0.6 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 0.6 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 2
- Sell 1
Today's price within the analysts' price targets
The average target of $24.5 is 66% above today's price. 73% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2023By product
- Product 100%
By region
- UNITED STATES 92%
- Non-US 7.5%
Product brings in 100% of revenue.
Segments in detail